Form 4: Crinetics Pharmaceuticals Director Boosts Equity Holdings with RSU and Option Grants

Crinetics Pharmaceuticals, Inc. Director Wendall Wierenga acquired 6,900 restricted stock units and 10,350 stock options on June 11, 2025, aligning personal interests with long-term company performance.

Summary

• Crinetics Pharmaceuticals, Inc. Director Wendall Wierenga acquired 6,900 shares of common stock in the form of restricted stock units (RSUs) on June 11, 2025.
• These RSUs were granted at a price of $0, indicating they are part of a compensation package.
• The RSUs are set to vest 100% on the earlier of the first anniversary of the grant date or the next annual meeting of the Issuer's stockholders, contingent on continued service on the board.
• Wierenga also acquired 10,350 stock options with an exercise price of $32.33 on the same date.
• These stock options will vest under the same conditions as the RSUs and have an expiration date of June 11, 2035.
• Following these transactions, Director Wierenga directly beneficially owns 116,146 shares of common stock and 10,350 stock options.

Sentiment

Score: 7

Explanation: The acquisition of shares and options by a director is generally a positive signal, indicating insider confidence and aligning interests with shareholders. As a routine compensation event, it's not overwhelmingly positive but certainly not negative.

Positives

• The acquisition of additional equity (restricted stock units and stock options) by a director signals confidence in the company's future prospects.
• The equity grants align the director's financial interests directly with the long-term performance and shareholder value of Crinetics Pharmaceuticals, Inc.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon the reporting person's continued service on the board of directors of Crinetics Pharmaceuticals, Inc.
• The ultimate value realized from these equity grants is subject to the future market price fluctuations of Crinetics Pharmaceuticals, Inc. common stock.

Future Outlook

The vesting schedules for the acquired restricted stock units and stock options indicate a future commitment from the director, aligning their incentives with the company's performance over the next year or until the next annual meeting of stockholders.

Industry Context

This Form 4 filing details a routine insider transaction, specifically the grant of equity compensation to a director. Such grants are a common practice across all industries, particularly in the biotechnology and pharmaceutical sectors, to incentivize long-term commitment, retain talent, and align the interests of directors and executives with those of shareholders, given the often lengthy development cycles and regulatory processes inherent to the industry.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) and stock options to directors is a standard component of executive and director compensation packages across publicly traded companies, especially prevalent in the U.S. biotechnology and pharmaceutical sectors.
• The specified vesting schedule, which is tied to continued service and either a one-year anniversary or the next annual meeting, is a typical structure for director equity compensation, designed to promote retention and long-term strategic oversight.
• The exercise price of $32.33 for the stock options would typically be set at or above the market price of CRNX stock on the grant date, a common practice for incentive-based option grants.

Stakeholder Impact

• Shareholders: The acquisition of equity by a director aligns their interests with shareholders, potentially signaling confidence in the company's future performance and commitment to long-term value creation.

Next Steps

• The acquired restricted stock units and stock options will vest on the earlier of the first anniversary of the grant date (June 11, 2026) or the next annual meeting of Crinetics Pharmaceuticals, Inc. stockholders, subject to continued service.

Key Dates

Keywords

Crinetics Pharmaceuticals, CRNX, SEC Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership